Chronic intermittent hypoxia induces atherosclerosis by NF-κB-dependent mechanisms

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1822, Issue 11, 2012, Pages 1650-1659

  Song, D ^a   Fang, G ^a   Mao, S Z ^a   Ye, X ^a   Liu, G ^a   Gong, Y ^b   Liu, S F ^a,b  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Cardiovascular risk factor; Intermittent hypoxia; Nuclear factor kappa B; Obstructive sleep apnea

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ROOT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHRONIC INTERMITTENT HYPOXIA; CONTROLLED STUDY; ENZYME ACTIVATION; GENE DELETION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN BLOTTING; WILD TYPE;

MUS;

EID: 84865048729     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2012.07.010     Document Type: Article

References (48)

1. Young T., Palta M., Dempsey J., Skatrud J., Weber S., Badr S. The occurrence of sleep-disordered breathing among middle-aged adults. N. Engl. J. Med. 1993, 328:1230-1235.
2. Mooe T., Franklin K.A., Holmstrom K., Rabben T., Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am. J. Respir. Crit. Care Med. 2001, 164:1910-1913.
3. Lévy P., Pépin J.L., Arnaud C., Baguet J.P., Dematteis M., Mach F. Obstructive sleep apnea and atherosclerosis. Prog. Cardiovasc. Dis. 2009, 51:400-410.
4. Drager L.F., Polotsky V.Y., Lorenzi-Filho G. Obstructive sleep apnea: an emerging risk factor for atherosclerosis. Chest 2011, 140:534-542.
5. Bradley T.D., Floras J.S. Obstructive sleep apnoea and its cardiovascular consequences. Lancet 2009, 373:82-93.
6. Mokhlesi B., Gozal D. Update in sleep medicine 2010. Am. J. Respir. Crit. Care Med. 2010, 181:545-549.
7. Yaggi H.K., Concato J., Kernan W.N., Lichtman J.H., Brass L.M., Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. N. Engl. J. Med. 2005, 353:2034-2041.
8. Fletcher E.C., Costarangos C., Miller T. The rate of fall of arterial oxyhemoglobin saturation in obstructive sleep apnea. Chest 1989, 96:717-722.
9. Flemons W.W. Clinical Practice: Obstructive sleep apnea. N. Engl. J. Med. 2002, 347:498-504.
10. Fletcher E.C. Invited review: physiological consequences of intermittent hypoxia: systemic blood pressure. J. Appl. Physiol. 2001, 90:1600-1605.
11. Savransky V., Nanayakkara A., Li J., Bevans S., Smith P.L., Rodriguez A., Polotsky V.Y. Chronic intermittent hypoxia induces atherosclerosis. Am. J. Respir. Crit. Care Med. 2007, 175:1290-1297.
12. Savransky V., Jun J., Li J., Nanayakkara A., Fonti S., Moser A.B., Steele K.E., Schweitzer M.A., Patil S.P., Bhanot S., Schwartz A.R., Polotsky V.Y. Dyslipidemia and atherosclerosis induced by chronic intermittent hypoxia are attenuated by deficiency of stearoyl coenzyme A desaturase. Circ. Res. 2008, 103:1173-1180.
13. Jun J., Reinke C., Bedja D., Berkowitz D., Bevans-Fonti S., Li J., Barouch L.A., Gabrielson K., Polotsky V.Y. Effect of intermittent hypoxia on atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2010, 209:381-386.
14. Li R.C., Haribabu B., Mathis S.P., Kim J., Gozal D. Leukotriene B4 receptor-1 mediates intermittent hypoxia-induced atherogenesis. Am. J. Respir. Crit. Care Med. 2011, 184:124-131.
15. Arnaud C., Poulain L., Levy P., Dematteis M. Inflammation contributes to the atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice. Atherosclerosis 2011, 219:425-431.
16. Li J., Thorne L.N., Punjabi N.M., Sun C.K., Schwartz A.R., Smith P.L., Marino R.L., Rodriguez A., Hubbard W.C., O'Donnell C.P., Polotsky V.Y. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ. Res. 2005, 97:698-706.
17. Greenberg H., Ye X., Wilson D., Htoo A.K., Henderson T., Liu S.F. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem. Biophys. Res. Commun. 2006, 343:591-596.
18. Htoo A.K., Greenberg H., Tongia S., Chen G., Henderson T., Wilson D., Liu S.F. Activation of nuclear factor kappaB in obstructive sleep apnea: a pathway leading to systemic inflammation. Sleep Breath. 2006, 10:43-50.
19. Ryan S., Taylor C.T., McNicholas W.T. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005, 112:2660-2667.
20. Ryan S., Taylor C.T., McNicholas W.T. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome?. Thorax 2009, 64:631-636.
21. Dyugovskaya L., Polyakov A., Ginsberg D., Lavie P., Lavie L. Molecular pathways of spontaneous and TNF-{alpha}-mediated neutrophil apoptosis under intermittent hypoxia. Am. J. Respir. Cell Mol. Biol. 2011, 45:154-162.
22. Arnaud C., Beguin P.C., Lantuejoul S., Pepin J.L., Guillermet C., Pelli G., Burger F., Buatois V., Ribuot C., Baguet J.P., Mach F., Levy P., Dematteis M. The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am. J. Respir. Crit. Care Med. 2011, 184:724-731.
23. de Frutos S., Duling L., Alò D., Berry T., Jackson-Weaver O., Walker M., Kanagy N., González Bosc L. NFATc3 is required for intermittent hypoxia-induced hypertension. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H2382-H2390.
24. Drager L.F., Li J., Shin M.K., Reinke C., Aggarwal N.R., Jun J.C., Bevans-Fonti S., Sztalryd C., O'Byrne S.M., Kroupa O., Olivecrona G., Blaner W.S., Polotsky V.Y. Intermittent hypoxia inhibits clearance of triglyceride-rich lipoproteins and inactivates adipose lipoprotein lipase in a mouse model of sleep apnoea. Eur. Heart J. 2012, 33:783-790.
25. Phillips C.L., Yee B.J., Marshall N.S., Liu P.Y., Sullivan D.R., Grunstein R.R. Continuous positive airway pressure reduces postprandial lipidemia in obstructive sleep apnea: a randomized, placebo-controlled crossover trial. Am. J. Respir. Crit. Care Med. 2011, 184(3):355-361.
26. Liu S.F., Malik A.B. NF-κB activation as a pathologic mechanism of septic shock and inflammation. Am. J. Physiol. Lung Cell. Mol. Physiol. 2006, 290:L622-L645.
27. Purkayastha S., Zhang G., Cai D. Uncoupling the mechanisms of obesity and hypertension by targeting hypothalamic IKK-β and NF-κB. Nat. Med. 2011, 17:883-887.
28. Cai D., Yuan M., Frantz D.F., Melendez P.A., Hansen L., Lee J., Shoelson S.E. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF- kappaB. Nat. Med. 2005, 11:183-190.
29. Chiang S.H., Bazuine M., Lumeng C.N., Geletka L.M., Mowers J., White N.M., Ma J.T., Zhou J., Qi N., Westcott D., Delproposto J.B., Blackwell T.S., Yull F.E., Saltiel A.R. The protein kinase IKKepsilon regulates energy balance in obese mice. Cell 2009, 138:961-975.
30. Gao Z., Yin J., Zhang J., He Q., McGuinness O.P., Ye J. Inactivation of NF-kappaB p50 leads to insulin sensitization in liver through post-translational inhibition of p70S6K. J. Biol. Chem. 2009, 284:18368-18376.
31. Yang H., Roberts L.J., Shi M.J., Zhou L.C., Ballard B.R., Richardson A., Guo Z.M. Retardation of atherosclerosis by overexpression of catalase or both Cu/Zn- superoxide dismutase and catalase in mice lacking apolipoprotein. Circ. Res. 2004, 95:1075-1081.
32. van Vlijmen B.J., van den Maagdenberg A.M., Gijbels M.J., van der Boom H., HogenEsch H., Frants R.R., Hofker M.H., Havekes L.M. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 1994, 93:1403-1410.
33. Liu S.F., Ye X.B., Malik A.B. In vivo inhibition of NF-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J. Immunol. 1997, 159:3976-3983.
34. Ding J., Song D., Ye X., Liu S.F. A pivotal role of endothelial-specific NF-κB signaling in the pathogenesis of septic shock and septic vascular dysfunction. J. Immunol. 2009, 183:4031-4038.
35. Lee E.J., Woodske M.E., Zou B., O'Donnell C.P. Dynamic arterial blood gas analysis in conscious, unrestrained C57BL/6J mice during exposure to intermittent hypoxia. J. Appl. Physiol. 2009, 107:290-294.
36. Vallabhapurapu S., Matsuzawa A., Zhang W., Tseng P.H., Keats J.J., Wang H., Vignali D.A., Bergsagel P.L., Karin M. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nat. Immunol. 2008, 9:1364-1370.
37. Brånén L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2137-2142.
38. Huber S.A., Sakkinen P., Conze D., Hardin N., Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2364-2367.
39. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998, 394:894-897.
40. Kuhlencordt P.J., Chen J., Han F., Astern J., Huang P.L. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001, 103:3099-3104.
41. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 2005, 52:1685-1695.
42. Steinberg D. Hypercholesterolemia and inflammation in atherogenesis: two sides of the same coin. Mol. Nutr. Food Res. 2005, 49:995-998.
43. Chen M., Li W., Wang N., Zhu Y., Wang X. ROS and NF-kappaB but not LXR mediate IL-1beta signaling for the downregulation of ATP-binding cassette transporter A1. Am. J. Physiol. Cell Physiol. 2007, 292:C1493-C1501.
44. Ferreira V., van Dijk K.W., Groen A.K., Vos R.M., van der Kaa J., Gijbels M.J., Havekes L.M., Pannekoek H. Macrophage-specific inhibition of NF-kappaB activation reduces foam-cell formation. Atherosclerosis 2007, 192:283-290.
45. Lei L., Xiong Y., Chen J., Yang J.B., Wang Y., Yang X.Y., Chang C.C., Song B.L., Chang T.Y., Li B.L. TNF-alpha stimulates the ACAT1 expression in differentiating monocytes to promote the CE-laden cell formation. J. Lipid Res. 2009, 50:1057-1067.
46. McLaren J.E., Ramji D.P. Interferon gamma: A master regulator of atherosclerosis Interferon gamma: a master regulator of atherosclerosis. Cytokine Growth Factor Rev. 2009, 20:125-135.
47. Webb N.R., Moore K.J. Macrophage-derived foam cells in atherosclerosis: Lessons from murine models and implications for therapy. Curr. Drug Targets 2007, 8:1249-1263.
48. Verreth W., De Keyzer D., Pelat M., Verhamme P., Ganame J., Bielicki J.K., Mertens A., Quarck R., Benhabilès N., Marguerie G., Mackness B., Mackness M., Ninio E., Herregods M.C., Balligand J.L., Holvoet P. Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004, 110:3259-3269.